Search research articles
Contact Us
Filters
Showing results (81-90 of 100) with videos related to
Page
of 10
Sort By:
British Journal of Cancer
|
December 15, 2023
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
Albert Font, Begona Mellado, Miguel A Climent, et al.
The New England Journal of Medicine
|
February 18, 2017
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J Vaughn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 9, 2022
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up
A V Balar, D E Castellano, P Grivas, et al.
European Urology
|
December 13, 2002
Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG)
J R Germà-Lluch, X Garcia del Muro, P Maroto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2019
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Y Fradet, J Bellmunt, D J Vaughn, et al.
International Journal of Cancer
|
July 24, 2019
PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma
Juan M Roldan-Romero, Benoit Beuselinck, María Santos, et al.
Cancer Research Communications
|
April 26, 2024
First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study
Duncan A Wheatley, Rossana Berardi, Miguel A Climent Duran, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 13, 2022
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
Miguel A Climent, Albert Font, Ignacio Durán, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 9, 2022
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT
Prudence A Francis, Gini F Fleming, István Láng, et al.
European Urology Open Science
|
October 30, 2024
Prostate-specific Antigen at 3 Months as a Predictor of Radiologic Progression-free Survival in Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-world Database
Mario Hassi Roman, Kinga Mate, Pedro De Pablos-Rodriguez, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 100) with videos related to
Sort By:
Page
of 10
British Journal of Cancer
|
December 15, 2023
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
Albert Font, Begona Mellado, Miguel A Climent, et al.
The New England Journal of Medicine
|
February 18, 2017
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J Vaughn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 9, 2022
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up
A V Balar, D E Castellano, P Grivas, et al.
European Urology
|
December 13, 2002
Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG)
J R Germà-Lluch, X Garcia del Muro, P Maroto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2019
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Y Fradet, J Bellmunt, D J Vaughn, et al.
International Journal of Cancer
|
July 24, 2019
PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma
Juan M Roldan-Romero, Benoit Beuselinck, María Santos, et al.
Cancer Research Communications
|
April 26, 2024
First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study
Duncan A Wheatley, Rossana Berardi, Miguel A Climent Duran, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 13, 2022
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
Miguel A Climent, Albert Font, Ignacio Durán, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 9, 2022
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT
Prudence A Francis, Gini F Fleming, István Láng, et al.
European Urology Open Science
|
October 30, 2024
Prostate-specific Antigen at 3 Months as a Predictor of Radiologic Progression-free Survival in Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-world Database
Mario Hassi Roman, Kinga Mate, Pedro De Pablos-Rodriguez, et al.
Page
of 10